Abstract
The results are reported of a small double-blind controlled trial on the effect of azathioprine in multiple sclerosis. Although a trend in favour of the treated group, as regards the effect on the disability, was found, it did not reach statistical significant levels. No influence was found on the relapse rate. The influence of side-effects, which were found in the treated group in a higher percentage than in the placebo group, on the results is discussed.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
